FGF19 Promotes the Proliferation and Insulin Secretion from Human
                    Pancreatic β Cells Via the IRS1/GLUT4 Pathway

Ting Zeng; Xi Tang; Xiaosu Bai; Haiyan Xiong

doi:10.1055/a-2250-7830

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2024; 132(03): 152-161
DOI: 10.1055/a-2250-7830

Article

FGF19 Promotes the Proliferation and Insulin Secretion from Human Pancreatic β Cells Via the IRS1/GLUT4 Pathway

Ting Zeng

¹Department of Endocrinology, Longhua District People’s Hospital of Shenzhen, Shenzhen, China

,

Xi Tang

²Department of Cardiology, Longhua District People’s Hospital of Shenzhen, Shenzhen, China

,

Xiaosu Bai

¹Department of Endocrinology, Longhua District People’s Hospital of Shenzhen, Shenzhen, China

,

Haiyan Xiong

³Department of Nursing, Longhua District People’s Hospital of Shenzhen, Shenzhen, China

› Author Affiliations

Abstract

Background Type 2 diabetes mellitus (T2DM) is a commonly observed complication associated with obesity. The effect of fibroblast growth factor 19 (FGF19), a promising therapeutic agent for metabolic disorders, on pancreatic β cells in obesity-associated T2DM remains poorly understood.

Methods Human pancreatic β cells were cultured with high glucose (HG) and palmitic acid (PA), followed by treatment with FGF19. The cell proliferation, apoptosis, and insulin secretion were evaluated by CCK-8, qRT-PCR, ELISA, flow cytometry, and western blotting. The expression of the insulin receptor substrate (IRS)/glucose transporter (GLUT) pathway was evaluated. The interaction between FGF19 and IRS1 was predicted using the STRING database and verified by co-immunoprecipitation and immunofluorescence. The regulatory effects of the IRS1/GLUT4 pathway on human pancreatic β cells were assessed by overexpressing IRS1 and silencing IRS1 and GLUT4.

Results HG+PA treatment reduced the human pancreatic β cell proliferation and insulin secretion and promoted cell apoptosis. However, FGF19 treatment restored these alterations and significantly increased the expressions of IRS1, GLUT1, and GLUT4 in the IRS/GLUT pathway. Furthermore, FGF19 and IRS1 were found to interact. IRS1 overexpression partially promoted the proliferation of pancreatic β cells and insulin secretion through GLUT4. Additionally, the silencing of IRS1 or GLUT4 attenuated the therapeutic effects of FGF19.

Conclusion In conclusion, FGF19 partly promoted the proliferation and insulin secretion of human pancreatic β cells and inhibited apoptosis by upregulating the IRS1/GLUT4 pathway. These findings establish a theoretical framework for the clinical utilization of FGF19 in the treatment of obesity-associated T2DM.

Keywords

fibroblast growth factor 19 - type 2 diabetes mellitus, - IRS1/GLUT4 pathway - human pancreatic β cells - insulin secretion

Full Text

References

References
1 Ahmad E, Lim S, Lamptey R. et al. Type 2 diabetes. Lancet 2022; 400: 1803-1820
2 Boland BB, Rhodes CJ, Grimsby JS. The dynamic plasticity of insulin production in β-cells. Mol Metab 2017; 6: 958-973
3 Lin JS, Dong HL, Chen GD. et al. Erythrocyte saturated fatty acids and incident type 2 diabetes in Chinese men and women: A prospective cohort study. Nutrients 2018; 10
4 Lu H, Hao L, Li S. et al. Elevated circulating stearic acid leads to a major lipotoxic effect on mouse pancreatic beta cells in hyperlipidaemia via a miR-34a-5p-mediated PERK/p53-dependent pathway. Diabetologia 2016; 59: 1247-1257
5 Pappachan JM, Fernandez CJ, Chacko EC. Diabesity and antidiabetic drugs. Mol Aspects Med 2019; 66: 3-12
6 Magkos F, Hjorth MF, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020; 16: 545-555
7 Portero McLellan KC, Wyne K, Villagomez ET. et al. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag 2014; 10: 173-188
8 Ruan D, Liu Y, Wang X. et al. miR-149-5p protects against high glucose-induced pancreatic beta cell apoptosis via targeting the BH3-only protein BIM. Exp Mol Pathol 2019; 110: 104279
9 Guo A, Li K, Tian HC. et al. FGF19 protects skeletal muscle against obesity-induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT-1/PGC-α pathway. J Cell Mol Med 2021; 25: 3585-3600
10 Potthoff MJ, Boney-Montoya J, Choi M. et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab 2011; 13: 729-738
11 Tomlinson E, Fu L, John L. et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143: 1741-1747
12 Zhao S, Wang D, Li Z. et al. FGF15/FGF19 alleviates insulin resistance and upregulates placental IRS1/GLUT expression in pregnant mice fed a high-fat diet. Placenta 2021; 112: 81-88
13 Yang Z, Wu F, He Y. et al. A novel PTP1B inhibitor extracted from Ganoderma lucidum ameliorates insulin resistance by regulating IRS1-GLUT4 cascades in the insulin signaling pathway. Food Funct 2018; 9: 397-406
14 Song Z, Ma J, Lu Y. et al. The protective role of the MKP-5-JNK/P38 pathway in glucolipotoxicity-induced islet β-cell dysfunction and apoptosis. Exp Cell Res 2019; 382: 111467
15 Deng S, Yang L, Ma K. et al. Astragalus polysaccharide improve the proliferation and insulin secretion of mouse pancreatic β cells induced by high glucose and palmitic acid partially through promoting miR-136-5p and miR-149-5p expression. Bioengineered 2021; 12: 9872-9884
16 Gadaleta RM, Moschetta A. Metabolic Messengers: Fibroblast growth factor 15/19. Nat Metab 2019; 1: 588-594
17 Seok S, Kemper JK. Paradoxical feeding activation of gut lipophagy by FGF15/FGF19-NR0B2/SHP-TFEB. Autophagy 2023; 19: 742-743
18 Xie M, Lin Z, Ji X. et al. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol 2023; 79: 109-125
19 Lu J, Liu Z, Zhao Y. et al. FGF19 improves sevoflurane-induced cognitive dysfunction in rats through the PGC-1α/BDNF/FNDC5 pathway. Tissue Cell 2023; 81: 102012
20 Morón-Ros S, Uriarte I, Berasain C. et al. FGF15/19 is required for adipose tissue plasticity in response to thermogenic adaptations. Mol Metab 2021; 43: 101113
21 Jin L, Yang R, Geng L. et al. Fibroblast growth factor-based pharmacotherapies for the treatment of obesity-related metabolic complications. Annu Rev Pharmacol Toxicol 2023; 63: 359-382
22 Tian H, Zhang S, Liu Y. et al. Fibroblast growth factors for nonalcoholic fatty liver disease: Opportunities and challenges. Int J Mol Sci 2023; 24
23 Kir S, Beddow SA, Samuel VT. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011; 331: 1621-1624
24 Fu L, John LM, Adams SH. et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145: 2594-2603
25 Marcelin G, Jo YH, Li X. et al. Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Mol Metab 2014; 3: 19-28
26 Ryan KK, Kohli R, Gutierrez-Aguilar R. et al. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 2013; 154: 9-15
27 Morton GJ, Matsen ME, Bracy DP. et al. FGF19 action in the brain induces insulin-independent glucose lowering. J Clin Invest 2013; 123: 4799-4808
28 Ruze R, Liu T, Zou X. et al. Obesity and type 2 diabetes mellitus: Connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne) 2023; 14: 1161521
29 Ibrahim HIM. Epigenetic regulation of obesity-associated type 2 diabetes. Medicina (Kaunas) 2022; 58
30 Bao S, Wang X, Cho SB. et al. Agriophyllum oligosaccharides ameliorate diabetic insulin resistance through INS-R/IRS/Glut4-mediated insulin pathway in db/db mice and MIN6 cells. Front Pharmacol 2021; 12: 656220
31 Wu R, Jian T, Ding X. et al. Total sesquiterpene glycosides from loquat leaves ameliorate HFD-induced insulin resistance by modulating IRS-1/GLUT4, TRPV1, and SIRT6/Nrf2 signaling pathways. Oxid Med Cell Longev 2021; 2021: 4706410
32 Wu Z, Yu W, Ni W. et al. Improvement of obesity by Liupao tea is through the IRS-1/PI3K/AKT/GLUT4 signaling pathway according to network pharmacology and experimental verification. Phytomedicine 2023; 110: 154633
33 Abudujilile D, Wang W, Aimaier A. et al. Cistanche tubulosa phenylethanoid glycosides suppressed adipogenesis in 3T3-L1 adipocytes and improved obesity and insulin resistance in high-fat diet induced obese mice. BMC Complement Med Ther 2022; 22: 270
34 Dai C, Wang X, Wu Y. et al. Polarity protein AF6 controls hepatic glucose homeostasis and insulin sensitivity by modulating IRS1/AKT insulin pathway in an SHP2-dependent manner. Diabetes 2019; 68: 1577-1590
35 Wang Y, Wen L, Zhou S. et al. Effects of four weeks intermittent hypoxia intervention on glucose homeostasis, insulin sensitivity, GLUT4 translocation, insulin receptor phosphorylation, and Akt activity in skeletal muscle of obese mice with type 2 diabetes. PLoS One 2018; 13: e0203551
36 Cui F, He X. IGF-1 ameliorates streptozotocin-induced pancreatic β cell dysfunction and apoptosis via activating IRS1/PI3K/Akt/FOXO1 pathway. Inflamm Res 2022; 71: 669-680
37 Takatani T, Shirakawa J, Roe MW. et al. IRS1 deficiency protects β-cells against ER stress-induced apoptosis by modulating sXBP-1 stability and protein translation. Sci Rep 2016; 6: 28177
38 Marafie SK, Al-Shawaf EM, Abubaker J. et al. Palmitic acid-induced lipotoxicity promotes a novel interplay between Akt-mTOR, IRS-1, and FFAR1 signaling in pancreatic β-cells. Biol Res 2019; 52: 44
39 Wang H, Ai J, Shopit A. et al. Protection of pancreatic β-cell by phosphocreatine through mitochondrial improvement via the regulation of dual AKT/IRS-1/GSK-3β and STAT3/Cyp-D signaling pathways. Cell Biol Toxicol 2022; 38: 531-551